Author  
Place of duty  
Title   암환자의 세포면역계에 대한 저용량 Cyclophosphamide 와 Polysaccharide K ( Copolang ) 의 병합치료 효과 ( Effect of Low Dose Cyclophosphamide and Polysaccharide K ( Copolang ) Combination Therapy on the Cell - Mediated Immunity in Cancer Patients and Primary Hepatocellular Carcino
Publicationinfo   1990 Jan; 022(02): 316-323.
Key_word  
Full-Text  
Abstract   To evaluate the combined therapeutic effect of Polysaccharide K and low dose cyclophosphamide, cyclophosphamide 300 mg/m IV Day 1 and PSK (Copolang 3 gm/Day, po, Day 4-17) were adminis- tered every 4 weeks in 16 patients with cancer including 10 patients with gastric cancer after surgery, 1 patient with duodenal cancer, 2 patients with pancreatic cancer, 1 patient with nasopharyngeal cancer, and 2 patients with bladder cancer. Peripheral blood T-cell subsets were measured by indirect fluorescent staining of peripheral lymphocytes with specific monoclonal antibodies against CD3, CD4 and CD8. The results are summerized as follows: 1) The mean value of percentage of CD4+ and CD4+/CD8+ ratio was increased, and the percentage of CDS+ was decreased after therapy, with statistical significance. 2) For durg toxicity, nausea & indigestion (grade 1 gastrointestinal toxicity) were complained in 3 patients (18%), and mild pruritus in 1 patient (9%). 3) There was no disease progression or disease recurrence during the period of this study. Duration of follow up was; median 8 months, range 4-16 months. In conclusion, copolang and low dose cyclophosphamide combination immunotherapy seems a useful modality in the therapy of a selected group of patients with cancer such as low risk surgical adjuvant setting, though longer follow up is needed to verify its effect on patient survival.
저 자   박철신(Cheol Shin Park),김종완(Jong Wan Kim),길준영(Jun Young Kil),김삼용(Sam Yong Kim)